Paying more than AFFO earns. The $1.90 quarterly dividend — $7.60 a year, held flat rather than raised — exceeded second-quarter AFFO of $1.83 per share, about a 104% payout, and the same pattern held for full-year 2025: $7.60 paid against $7.24 of AFFO, about 105%. That is the whole verdict in one line: the dividend currently outruns the cash the properties produce after upkeep. It is not a trap on the House definition — total return since inception in 2016 is 486% per the company, and no return-of-capital funding of the common dividend has been verified — but a 14.02% yield at a payout above 100% is pay for tenant risk, not a safe rate. Cannabis tenant defaults and lease terminations (PharmaCann, 4Front, Gold Flora, TILT, Cannabist, Parallel) have already cut revenue 13.8% in 2025, and the pivot into life sciences (a $270 million IQHQ investment) is still being funded.
Key risk: Tenant concentration in state-licensed cannabis: further defaults or lease terminations cut rent directly, and re-leasing specialized cultivation space is slow and expensive.
Changes if: AFFO per share falls further below the $1.90 rate, occupancy slips below the 95.8% of June 30, 2026, or the dividend is cut. A return to AFFO coverage would restore the grade.
- !AFFO coverage check: Q2 2026 AFFO was $53.0 million, or $1.83 per share, against the $1.90 dividend declared for the quarter — about a 104% payout. Full-year 2025 was the same story: $7.60 paid against $7.24 of AFFO, about 105%.
- !Yield check: 14.02% — $7.60 a year ÷ the $54.21 close on October 23, 2026. That sits in the distress band: it prices in a cut, and the dividend has already stopped growing.
- ✓Balance sheet check: Net debt to adjusted EBITDA was 1.7× at June 30, 2026 ($418.9 million of net debt), with $299.7 million of liquidity — leverage is not the problem; tenant cash flow is.
- !Growth check: No growth to report: the dividend is held at $1.90, revenue fell to $63.3 million in Q2 2026 on tenant defaults, and occupancy was 95.8% with an 11.9-year weighted average lease term at June 30, 2026.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.